Page last updated: 2024-11-12

holomycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

holomycin: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

holomycin : A dithiolopyrrolone antibiotic that is 4,5-dihydro[1,2]dithiolo[4,3-b]pyrrole in which the hydrogens at positions 5 and 6 have been replaced by oxo and acetamido groups, respectively. It is an inhibitor of DNA-dependent RNA polymerase, and exhibits antibacterial and antitumour properties. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID10262683
CHEMBL ID476226
CHEBI ID156451
SCHEMBL ID2722541
MeSH IDM0064414

Synonyms (32)

Synonym
brn 0188430
acetamide, n-(4,5-dihydro-5-oxo-1,2-dithiolo(4,3-b)pyrrol-6-yl)-
n-(4,5-dihydro-5-oxo-1,2-dithiolo(4,3-b)pyrrol-6-yl)acetamide
1,2-dithiolo(4,3-b)pyrrol-5(4h)-one, 6-acetamido-
n-(4,5-dihydro-5-oxo-1,2-dithiolo(4,3-b)pyrrol-6-yl)-n-methylformamide
n-demethylthiolutin
6-acetamido-1,2-dithiolo(4,3-b)pyrrol-5(4h)-one
holomycin
n-(4,5-dihydro-5-oxo-1,2-dithiolo-(4,3-b)pyrrol-6-yl)acetamide
n-{5-oxo-4h,5h-[1,2]dithiolo[4,3-b]pyrrol-6-yl}acetamide
n-(4,5-dihydro-5-oxo-1,2-dithiolo-[4,3-b]pyrrol-6-yl)acetamide
n-(5-oxo-4,5-dihydro[1,2]dithiolo[4,3-b]pyrrol-6-yl)acetamide
n-(5-oxo-4h-dithiolo[4,3-b]pyrrol-6-yl)acetamide
6-(acetylamino)-1,2-dithiolo[4,3-b]pyrrol-5(4h)-one
CHEBI:156451
6-acetamido-1,2-dithiolo[4,3-b]pyrrol-5(4h)-one
488-04-0
CHEMBL476226
n-(5-oxo-4h-dithiolo[3,4-d]pyrrol-6-yl)acetamide
unii-44cf65ylf8
44cf65ylf8 ,
1,2-dithiolo(4,3-b)pyrrol-5(4h)-one, 6-(acetylamino)-
holomycin [mi]
1,2-dithiolo(4,3-b)pyrrol-5(4h)-one, 6-acetamido
SCHEMBL2722541
DTXSID40197605
n-(4,5-dihydro-5-oxo-1,2-dithiolo[4,3-b]pyrrol-6-yl)acetamide
Q27258732
MS-23176
n-(5-oxo-4,5-dihydro-[1,2]dithiolo[4,3-b]pyrrol-6-yl)acetamide
CS-0113932
HY-135751

Research Excerpts

Overview

Holomycin is a member of the dithiolopyrrolone group of antibiotics. It has been isolated from several species of actinobacteria belonging to the genus Streptomyces and also from some Gram-negative bacteria.

ExcerptReferenceRelevance
"Holomycin is a member of the dithiolopyrrolone group of antibiotics, and has already been isolated from several species of actinobacteria belonging to the genus Streptomyces and also from some Gram-negative bacteria."( Saccharothrix algeriensis NRRL B-24137, the first non-Streptomyces actinobacterium, produces holomycin after cystine feeding.
Bouras, N; Coppel, Y; Mathieu, F; Merrouche, R; Sabaou, N; Yekkour, A; Zitouni, A, 2020
)
1.5
"Holomycin is a member of the dithiolopyrrolone class of secondary metabolites. "( Holomycin, a dithiolopyrrolone compound produced by Streptomyces clavuligerus.
Liras, P, 2014
)
3.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
chelatorA ligand with two or more separate binding sites that can bind to a single metallic central atom, forming a chelate.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
EC 2.7.7.6 (RNA polymerase) inhibitorAn EC 2.7.7.* (nucleotidyltransferase) inhibitor that interferes with the action of RNA polymerase (EC 2.7.7.6).
antibacterial agentA substance (or active part thereof) that kills or slows the growth of bacteria.
marine metaboliteAny metabolite produced during a metabolic reaction in marine macro- and microorganisms.
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
dithiolopyrrolone antibioticA class of antibiotics that possess the unique pyrrolinonodithiole (4H-[1,2]dithiolo[4,3-b]pyrrol-5-one) skeleton linked upto three variable acyl groups.
acetamidesCompounds with the general formula RNHC(=O)CH3.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
holomycin biosynthesis819

Bioassays (4)

Assay IDTitleYearJournalArticle
AID369453Inhibition of Staphylococcus epidermidis RNA polymerase mediated transcription2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro activities of different inhibitors of bacterial transcription against Staphylococcus epidermidis biofilm.
AID369451Antimicrobial activity against Staphylococcus epidermidis2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro activities of different inhibitors of bacterial transcription against Staphylococcus epidermidis biofilm.
AID369452Ratio of MBC for Staphylococcus epidermidis to MIC for Staphylococcus epidermidis2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro activities of different inhibitors of bacterial transcription against Staphylococcus epidermidis biofilm.
AID369459Inhibition of Staphylococcus epidermidis biofilm formation assessed as reduction of >2 log 10 bacterial count in biofilm after 24 hrs2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro activities of different inhibitors of bacterial transcription against Staphylococcus epidermidis biofilm.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (35)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (5.71)18.7374
1990's0 (0.00)18.2507
2000's6 (17.14)29.6817
2010's18 (51.43)24.3611
2020's9 (25.71)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.16

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.16 (24.57)
Research Supply Index3.58 (2.92)
Research Growth Index5.41 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.16)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (5.71%)6.00%
Case Studies0 (0.00%)4.05%
Observational1 (2.86%)0.25%
Other32 (91.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]